Influencing factors and clinical value of anti-aquaporin-4 antibody in cerebrospinal fluid: a study of 82 patients with neuromyelitis optica spectrum disorder
- 4 August 2025
- journal article
- research article
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 125 (5) , 1327-1334
Abstract
Objective Serum AQP4 antibody (AQP4-IgG) is the causative antibody of neuromyelitis optica spectrum disorder (NMOSD) but AQP4-IgG in cerebrospinal fluid (CSF) has been seldom studied. We aimed to explore the clinical value and influencing factors of CSF AQP4-IgG in NMOSD. Methods In this study, we screened 137 patients with NMOSD diagnosed according to the 2015 International Consensus Diagnostic Criteria (IPND criteria). From this cohort, paired CSF and serum samples were simultaneously collected from 82 patients (including seropositive and seronegative subgroups) for antibody titer measurement. We explored the relationship between CSF AQP4-IgG and patient’s clinical features. Their demographic, clinical, laboratory data and MRI images were collected and analyzed. Results 74 patients were seropositive for AQP4-IgG and 8 patients were seronegative. Among the 74 patients seropositive for AQP4-IgG, 46 were CSF-positive and 28 were CSF-negative, while none of the 8 seronegative patients were CSF-positive. CSF AQP4-IgG positive and negative patients showed significant differences in EDSS and relapse status. Out of the 82 patients, 67 patients were during relapse and only patients during relapse were included in the next analysis. Between the CSF-positive and CSF-negative patients, no significant differences were found in EDSS, relapse manifestation, CSF indicators, serum cytokine levels, lymphocyte subsets or MRI lesions. Responses to treatment during relapse and length of hospital stay showed no significant differences either. A positive correlation between the serum and CSF titers (rs: 0.64, p < 0.001) was found. Further binary logistic regression analysis revealed that CSF AQP4-IgG positivity was associated with serum AQP4-IgG titers and EDSS scores. Conclusions CSF AQP4-IgG positivity primarily results from passive diffusion of serum antibodies across the blood-brain barrier, which is different from the CNS-restricted antibody production in MOG-IgG associated disorders (MOGAD). Limited prognostic value of CSF AQP4-IgG was revealed in this study.Keywords
Funding Information
- Innovative Research Team of High-Level Local Universities in Shanghai (SHSMUZDCX20211901)
- New Quality Clinical Specialties of High-end Medical Disciplinary Construction in Pudong New Area (2024-PWXZ-16)
- Interdisciplinary Program of Shanghai Jiao Tong University (YG2023LC04)
- Shanghai “Rising Stars of Medical Talents” Youth Development Program
This publication has 32 references indexed in Scilit:
- Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumabAutoimmunity Reviews, 2025
- Real‐world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell‐based assayAnnals of Clinical and Translational Neurology, 2025
- MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessmentJournal of Neurology, 2024
- IL-6 as a marker for NMOSD disease activityJournal of Neuroimmunology, 2022
- Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis optica spectrum disorder patientsJournal of Neuroimmunology, 2021
- Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disordersJournal of Neuroimmunology, 2020
- Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter studyJournal of Neurology, 2018
- CNS Aquaporin‐4‐specific B cells connect with multiple B‐cell compartments in neuromyelitis optica spectrum disorderAnnals of Clinical and Translational Neurology, 2017
- Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disordersJournal of Neuroimmunology, 2011
- Intrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis opticaAnnals of Neurology, 2009